Margenza Injection, Solution, Concentrate
Product Images NDC 70720-022

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Margenza (NDC 70720-022). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Tersera Therapeutics Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Margenza 01)

A Kaplan-Meier survival curve chart displaying progression-free survival probability over time in months from initial randomization. Two treatment groups are compared: margetuximab plus chemotherapy (solid line) and trastuzumab plus chemotherapy (dotted line), with censored data points marked by plus symbols. Patient-at-risk numbers for each time interval are listed below the x-axis.*

FDA Label Image

Principal Display Panel (250 mg/10 mL Vial Carton)

Packaging label for Margenza (margetuximab-cmkb) Injection, concentrate for intravenous infusion. The label displays a strength of 250 mg per 10 mL (25 mg/mL) in a single-dose vial. Labeler is TerSera Therapeutics LLC. The label includes storage instructions, contents description, dosage form, and barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.